Ligand Pharm (LGND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 79,669 | -37,604 | -42,451 | -4,032 | 27,056 |
| Depreciation Amortization | 23,326 | 15,948 | 8,067 | 34,394 | 26,201 |
| Income taxes - deferred | 12,113 | -9,169 | -8,844 | -15,800 | -3,108 |
| Accounts receivable | -19,650 | -3,341 | -576 | -6,459 | -794 |
| Other Working Capital | -21,954 | -11,339 | -5,168 | 19,356 | 7,754 |
| Other Operating Activity | -70,060 | 35,859 | 23,527 | 69,588 | 11,467 |
| Operating Cash Flow | $3,444 | $-9,646 | $-25,445 | $97,047 | $68,576 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -349,877 | -8,703 | 3,780 | 36,114 | 70,758 |
| PPE Investments | -1,256 | -2,249 | -214 | -19,640 | -1,109 |
| Net Acquisitions | N/A | N/A | N/A | -91,996 | -91,996 |
| Purchase Of Investment | N/A | N/A | N/A | -998 | -998 |
| Purchase Sale Intangibles | N/A | 5,179 | 1,328 | 7,429 | N/A |
| Other Investing Activity | -8,085 | 5,179 | 1,328 | -67,144 | -81,696 |
| Investing Cash Flow | $-359,218 | $-5,773 | $4,894 | $-143,664 | $-105,041 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 460,000 | N/A | N/A | N/A | N/A |
| Debt Repayment | -113,250 | N/A | -7 | N/A | N/A |
| Common Stock Issued | 105,593 | 12,461 | 4,222 | 102,728 | 80,281 |
| Common Stock Repurchased | -15,000 | N/A | N/A | N/A | N/A |
| Other Financing Activity | -17,450 | -2,213 | -8,962 | -5,587 | -3,528 |
| Financing Cash Flow | $419,893 | $10,248 | $-4,747 | $97,141 | $76,753 |
| Exchange Rate Effect | 2,950 | 3,350 | 1,058 | -1,171 | 377 |
| Beginning Cash Position | 72,307 | 72,307 | 72,307 | 22,954 | 22,954 |
| End Cash Position | 139,376 | 67,669 | 47,989 | 72,307 | 63,619 |
| Net Cash Flow | $67,069 | $-4,638 | $-24,318 | $49,353 | $40,665 |
| Free Cash Flow | |||||
| Operating Cash Flow | 3,444 | -9,646 | -25,445 | 97,047 | 68,576 |
| Capital Expenditure | -1,256 | -2,249 | -214 | -19,640 | -1,109 |
| Free Cash Flow | 2,188 | -11,895 | -25,659 | 77,407 | 67,467 |